Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 988 | 85 | 896 |
| Samples | 357 | 50 | 304 |
| Peptides | 271 | 31 | 245 |
Function
ACVR2A · Activin A receptor type 2A
This gene encodes a receptor that mediates the functions of activins, which are members of the transforming growth factor-beta (TGF-beta) superfamily involved in diverse biological processes. The encoded protein is a transmembrane serine-threonine kinase receptor which mediates signaling by forming heterodimeric complexes with various combinations of type I and type II receptors and ligands in a cell-specific manner. The encoded type II receptor is primarily involved in ligand-binding and includes an extracellular ligand-binding domain, a transmembrane domain and a cytoplasmic serine-threonine kinase domain. This gene may be associated with susceptibility to preeclampsia, a pregnancy-related disease which can result in maternal and fetal morbidity and mortality. Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jun 2013].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 264 amino-acid changes on canonical ENST00000241416 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in ACVR2A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in ACVR2A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 3/42 7% | 20/612 3% |
| Colorectal Carcinoma | 6/143 4% | 63/3239 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Germ Cell Tumour | 2/25 8% | 1/169 1% |
| Hepatocellular Carcinoma | 1/46 2% | 34/2210 2% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Melanoma | 4/210 2% | 22/1899 1% |
| Chondrosarcoma | 0/14 0% | 1/75 1% |
| Gastric Carcinoma | 0/74 0% | 21/1809 1% |
| Cervical Carcinoma | 1/35 3% | 4/422 1% |
| Pancreatic Carcinoma | 0/89 0% | 16/1611 1% |
| Biliary Tract Carcinoma | 1/54 2% | 7/950 1% |
| Breast Carcinoma | 8/144 6% | 18/3264 1% |
| Neuroendocrine Tumour | 2/154 1% | 3/577 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Other Solid Cancers | 1/94 1% | 8/1515 1% |
| Kidney Carcinoma | 2/85 2% | 9/1862 0% |
| Ovarian Carcinoma | 0/109 0% | 6/998 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 4/1390 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Esophageal Carcinoma | 0/23 0% | 4/769 1% |
| Glioma | 0/52 0% | 10/2127 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Prostate Carcinoma | 2/13 15% | 6/2105 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Plasma Cell Myeloma | 1/44 2% | 0/305 0% |
Mutation Distribution
Where ACVR2A is mutated · all tissues, split by cell line vs tissue
How many mutations in ACVR2A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 988 mutations in ACVR2A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|